背景与目的同时性多原发肺癌(synchronous multiple primary lung cancer,sMPLC)既往属少见疾病,近年发病率呈持续上升趋势,但缺乏对其大样本的研究报道。本研究对357例s MPLC的临床病理资料进行分析总结,籍以为临床诊断、治疗及预后提...背景与目的同时性多原发肺癌(synchronous multiple primary lung cancer,sMPLC)既往属少见疾病,近年发病率呈持续上升趋势,但缺乏对其大样本的研究报道。本研究对357例s MPLC的临床病理资料进行分析总结,籍以为临床诊断、治疗及预后提供理论依据。方法参考Martini-Melamed诊断标准和国际肺癌研究协会(International Association for the Study of Lung Cancer,IASLC)第8版肿瘤-淋巴结-转移(tumor-node-metastasis,TNM)分期标准,对357例sMPLC的临床病理资料进行分析。结果 357例患者中,双原发病灶269例(75.35%),三原发病灶65例(18.21%),四原发病灶及以上者23例(6.44%),最多者为8个病灶。病灶好发于上叶,特别是右上叶(35.77%,298/833),病理类型以腺癌为主(95.56%,796/833),鳞癌次之(2.40%,20/833),腺癌亚型中以腺泡样为主的比例较高(70.81%,313/442),分期以Ib期及以下为主(68.35%,244/357)。病理类型相同者发病率(92.72%,331/357)远高于不同病理类型(7.28%,26/357),其中腺癌-腺癌比例较高(99.40%,329/331)。sMPLC的3年总生存率(overall survival,OS)为91.93%,5年总生存率为84.37%,多因素生存分析显示,有吸烟史(P=0.012)、最大病灶直径大于2 cm(P=0.027)、淋巴结转移(P=0.015)和胸膜受累(P<0.001)为影响sMPLC预后生存的独立危险因素。结论 sMPLC好发于右上叶,以腺癌最常见,腺泡样为主的亚型多见。吸烟史、最大结节直径、淋巴结转移和胸膜侵犯是影响sMPLC预后生存的独立危险因素。早期发现和积极的手术可以使sMPLC患者获得较好的预后。展开更多
The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a subset of patients with non-small cell lung cancer (NSCLC). Crizotinib (Xalkori) is an orally avai...The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a subset of patients with non-small cell lung cancer (NSCLC). Crizotinib (Xalkori) is an orally available small molecule tyrosine kinase inhibitor proven in clinical trials to significantly impact progression free survival and overall response rate. We present a case of a 56-year-old male with NSCLC whose lack of a positive treatment response to this therapy led to the clinical suspicion and identification of the underdiagnosed entity known as synchronous multiple primary lung cancer (SMPLC).展开更多
文摘背景与目的同时性多原发肺癌(synchronous multiple primary lung cancer,sMPLC)既往属少见疾病,近年发病率呈持续上升趋势,但缺乏对其大样本的研究报道。本研究对357例s MPLC的临床病理资料进行分析总结,籍以为临床诊断、治疗及预后提供理论依据。方法参考Martini-Melamed诊断标准和国际肺癌研究协会(International Association for the Study of Lung Cancer,IASLC)第8版肿瘤-淋巴结-转移(tumor-node-metastasis,TNM)分期标准,对357例sMPLC的临床病理资料进行分析。结果 357例患者中,双原发病灶269例(75.35%),三原发病灶65例(18.21%),四原发病灶及以上者23例(6.44%),最多者为8个病灶。病灶好发于上叶,特别是右上叶(35.77%,298/833),病理类型以腺癌为主(95.56%,796/833),鳞癌次之(2.40%,20/833),腺癌亚型中以腺泡样为主的比例较高(70.81%,313/442),分期以Ib期及以下为主(68.35%,244/357)。病理类型相同者发病率(92.72%,331/357)远高于不同病理类型(7.28%,26/357),其中腺癌-腺癌比例较高(99.40%,329/331)。sMPLC的3年总生存率(overall survival,OS)为91.93%,5年总生存率为84.37%,多因素生存分析显示,有吸烟史(P=0.012)、最大病灶直径大于2 cm(P=0.027)、淋巴结转移(P=0.015)和胸膜受累(P<0.001)为影响sMPLC预后生存的独立危险因素。结论 sMPLC好发于右上叶,以腺癌最常见,腺泡样为主的亚型多见。吸烟史、最大结节直径、淋巴结转移和胸膜侵犯是影响sMPLC预后生存的独立危险因素。早期发现和积极的手术可以使sMPLC患者获得较好的预后。
文摘The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a subset of patients with non-small cell lung cancer (NSCLC). Crizotinib (Xalkori) is an orally available small molecule tyrosine kinase inhibitor proven in clinical trials to significantly impact progression free survival and overall response rate. We present a case of a 56-year-old male with NSCLC whose lack of a positive treatment response to this therapy led to the clinical suspicion and identification of the underdiagnosed entity known as synchronous multiple primary lung cancer (SMPLC).
